Advisory Committee To Review GSK/Adolor’s Entereg
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms hope to get the drug on the market before Wyeth/Progenics’ competing methylnaltrexone for treatment of postoperative ileus.
You may also be interested in...
Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates
$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.
Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates
$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.
Wyeth Plans Methylnaltrexone Studies In New Patient Populations
Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.